Eisai and Biogen's Alzheimer's success leaves many questions still unanswered

When the celebrations over the companies’ recent Alzheimer’s breakthrough were over, some were left asking questions – like what about the treatment’s efficacy and side effects, and how much will it cost?

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Shares of Eisai Co. and partner Biogen Inc. have soared since reporting that their drug lecanemab slowed Alzheimer’s, the first to unambiguously impede the progression of the disease in a final-stage trial. But many questions linger.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs